T. A. Ban

985 total citations
73 papers, 709 citations indexed

About

T. A. Ban is a scholar working on Psychiatry and Mental health, Pharmacology and Molecular Biology. According to data from OpenAlex, T. A. Ban has authored 73 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Psychiatry and Mental health, 16 papers in Pharmacology and 10 papers in Molecular Biology. Recurrent topics in T. A. Ban's work include Schizophrenia research and treatment (14 papers), Electroconvulsive Therapy Studies (14 papers) and Treatment of Major Depression (14 papers). T. A. Ban is often cited by papers focused on Schizophrenia research and treatment (14 papers), Electroconvulsive Therapy Studies (14 papers) and Treatment of Major Depression (14 papers). T. A. Ban collaborates with scholars based in United States, Canada and Italy. T. A. Ban's co-authors include H. E. Lehmann, Joannis N. Nestoros, J. Ananth, Hector Warnes, H. Lehmann, John C. Pecknold, Jenny M. Lewis, Kenneth C. C. Yang, Mitchell B. Balter and E. H. Uhlenhuth and has published in prestigious journals such as American Journal of Psychiatry, Schizophrenia Bulletin and Chemical Science.

In The Last Decade

T. A. Ban

68 papers receiving 572 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. A. Ban United States 15 276 155 128 105 78 73 709
Ban Ta Canada 13 335 1.2× 183 1.2× 113 0.9× 69 0.7× 66 0.8× 110 617
Donald R. Kanter United States 13 354 1.3× 124 0.8× 134 1.0× 86 0.8× 109 1.4× 17 631
Burton J. Goldstein United States 14 233 0.8× 242 1.6× 198 1.5× 112 1.1× 102 1.3× 47 755
P Deniker France 17 435 1.6× 155 1.0× 222 1.7× 145 1.4× 137 1.8× 113 980
Ballenger Jc United States 15 327 1.2× 109 0.7× 128 1.0× 57 0.5× 99 1.3× 19 650
William M. Petrie United States 12 296 1.1× 218 1.4× 71 0.6× 119 1.1× 78 1.0× 33 839
Belmaker Rh Israel 13 354 1.3× 90 0.6× 113 0.9× 87 0.8× 127 1.6× 40 712
P. J. Perry United States 12 526 1.9× 216 1.4× 138 1.1× 101 1.0× 93 1.2× 20 872
Bo Siwers Sweden 17 292 1.1× 256 1.7× 228 1.8× 192 1.8× 40 0.5× 23 865
Jon F. Heiser United States 15 200 0.7× 144 0.9× 79 0.6× 43 0.4× 94 1.2× 30 567

Countries citing papers authored by T. A. Ban

Since Specialization
Citations

This map shows the geographic impact of T. A. Ban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. A. Ban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. A. Ban more than expected).

Fields of papers citing papers by T. A. Ban

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. A. Ban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. A. Ban. The network helps show where T. A. Ban may publish in the future.

Co-authorship network of co-authors of T. A. Ban

This figure shows the co-authorship network connecting the top 25 collaborators of T. A. Ban. A scholar is included among the top collaborators of T. A. Ban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. A. Ban. T. A. Ban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Li, T. A. Ban, Ruihao Li, et al.. (2025). A novel near-infrared fluorescent hERG potassium channel probe for glioblastoma therapy and imaging. Chemical Science. 16(46). 21962–21974.
2.
Ban, T. A.. (2001). Pharmacotherapy of depression: a historical analysis. Journal of Neural Transmission. 108(6). 707–716. 59 indexed citations
3.
Ban, T. A., P. Gaszner, Eugenio Aguglia, et al.. (1998). Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Human Psychopharmacology Clinical and Experimental. 13(S1). S29–S39. 50 indexed citations
4.
Ban, T. A.. (1992). PSYCHOPHARMACOLOGY AND SUCCESSFUL CEREBRAL AGING. Clinical Neuropharmacology. 15. 506A–507A. 1 indexed citations
5.
Ban, T. A.. (1984). PSYCHOPHARMACOLOGY AND PSYCH ATRIC DIAGNOSIS. CYCLIC ANTIDEPRESSANTS AND DEPRESSION. Clinical Neuropharmacology. 7. S222–S222. 1 indexed citations
6.
Wilson, William H., et al.. (1982). A double‐blind dose‐determination study with flutroline: A new neuroleptic. Drug Development Research. 2(4). 357–362. 1 indexed citations
7.
Guy, William, et al.. (1982). A Collaborative Study of a New Antidepressant,Viloxazine, in Neurotic and Endogenous Depressives. International Pharmacopsychiatry. 17(1). 36–42. 3 indexed citations
8.
McEvoy, Joseph P., et al.. (1982). Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical study.. PubMed. 43(3). 111–2. 2 indexed citations
9.
Petrie, William M., et al.. (1980). Viloxazine in the Treatment of Depressive Neurosis:A Placebo and Standard (Imipramine) Controlled Clinical Study. International Pharmacopsychiatry. 15(3). 193–196. 3 indexed citations
10.
Lehmann, H. E., et al.. (1976). A double-blind comparative clinical trial with maprotiline (Ludiomil) and imipramine in newly-admitted depressed patients.. PubMed. 19(4). 463–8. 6 indexed citations
11.
Pecknold, John C., et al.. (1975). A clinical trial with nomifensin, a new antidepressant drug.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 11(4). 304–8. 10 indexed citations
12.
Lehmann, H. E., et al.. (1972). Nicotinic Acid, Thioridazine, Fluoxymesterone and their Combinations in Hospitalized Geriatric Patients : A Systematic Clinical Study. Canadian Psychiatric Association Journal. 17(4). 315–320. 4 indexed citations
13.
Lehmann, H., et al.. (1970). Side Effects and Teratogenicity of Lithium Carbonate Treatment. PubMed. 10(6). 387–389. 36 indexed citations
14.
Ananth, J., T. A. Ban, H. E. Lehmann, & Jean Bennett. (1970). Nicotinic Acid in the Prevention and Treatment of Methionine-Induced Exacerbation of Psychopathology in Schizophrenics. Canadian Psychiatric Association Journal. 15(1). 15–20. 12 indexed citations
15.
Lehmann, H. E., et al.. (1970). A survey of extrapyramidal manifestations in the inpatient population of a psychiatric hospital.. PubMed. 41(7). 909–16. 11 indexed citations
16.
Lehmann, H. & T. A. Ban. (1969). Chemotherapy in Aged Psychiatric Patients . Canadian Psychiatric Association Journal. 14(4). 361–369. 1 indexed citations
17.
Silver, Diana, H. E. Lehmann, V. A. Kral, & T. A. Ban. (1968). Selection and Prediction of Therapeutic Responsiveness in Geriatric Patients. Canadian Psychiatric Association Journal. 13(6). 561–563. 4 indexed citations
18.
Ban, T. A.. (1967). Book Review: Pavlovian Psychiatry, A New Synthesis.. Canadian Psychiatric Association Journal. 12(6). 622–622. 2 indexed citations
19.
Ban, T. A., et al.. (1966). Conditional Reflex Studies in Depression. Canadian Psychiatric Association Journal. 11(1_suppl). 98–104. 6 indexed citations
20.
Ban, T. A., et al.. (1961). Observations on the Action of Sernyl — A New Psychotropic Drug. Canadian Psychiatric Association Journal. 6(3). 150–157. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026